Who are BL 1020 High Dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ropinirole CR-RLS, IM aripiprazole once monthly, Raclopride C11, Ropinirole (Requip), [11C]raclopride, Amisulpride add-on.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bl-1020-high-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BL 1020 High Dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BL 1020 High Dose (BL 1020 High Dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine D3 receptor antagonist. Area: Psychiatry.

phase 2 Dopamine D3 receptor antagonist Dopamine D3 receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

BL 1020 High Dose (BL 1020 High Dose) — BioLineRx, Ltd.. BL 1020 is a dopamine D3 receptor antagonist that modulates dopaminergic signaling in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BL 1020 High Dose TARGET	BL 1020 High Dose	BioLineRx, Ltd.	phase 2	Dopamine D3 receptor antagonist	Dopamine D3 receptor
ropinirole CR-RLS	ropinirole CR-RLS	GlaxoSmithKline	marketed	Dopamine D2/D3 receptor agonist	Dopamine D2 receptor, Dopamine D3 receptor
IM aripiprazole once monthly	IM aripiprazole once monthly	University of Utah	marketed	Atypical antipsychotic	Dopamine D2 receptor, Dopamine D3 receptor
Raclopride C11	Raclopride C11	University of North Carolina, Chapel Hill	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor
Ropinirole (Requip)	Ropinirole (Requip)	St. Luke's-Roosevelt Hospital Center	marketed	Dopamine D2/D3 receptor agonist	Dopamine D2 receptor, Dopamine D3 receptor
[11C]raclopride	[11C]raclopride	New York State Psychiatric Institute	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor
Amisulpride add-on	Amisulpride add-on	National Health Research Institutes, Taiwan	marketed	Atypical antipsychotic	Dopamine D2 receptor, Dopamine D3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine D3 receptor antagonist class)

BioLineRx, Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BL 1020 High Dose — Competitive Intelligence Brief. https://druglandscape.com/ci/bl-1020-high-dose. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing